THALIDOMIDE FOR THE TREATMENT OF BIOCHEMICALLY RECURRENT PROSTATE CANCER (PSA Recurrence)
According to a randomized study run and reported by William D.Figg, PharmD, head of the Molecular Pharmacology Section of the Centerfor Cancer Research at the National Cancer Institute, in Bethesda, MD. And published online January [...]
Fear and Hope
Inside all of us is fear Inside all of us is hope Inside all of us is the ability to use our hope to conquer our fear Joel T Nowak MA, MSW
Abiraterone Acetate (CB7630) Phase II Data Released At The ASCO Annual Meeting
At the ASCO Annual meeting in Orlando Florida, Cougar Biotechnology, Inc. announced perliminary results from their ongoing Phase II clinical trials of their much discussed investigational drug abiraterone acetate (CB7630). The company released some preliminary [...]
Late Stage Clinical Trials
I compiled a list of trials that are activily recruiting men with hormone refractory prostate cancer (HRPC) who have also failed chemotherapy (taxotere). Being at this point in the disease process is by far the [...]
Time to Biochemical Failure and PSADT As Prognosticators To Metastatic Disease
A known fact is that between 15% to 35% of men who have surgery as their primary treatment after diagnosis of prostate cancer will experience a biochemical recurrence (BCR). The authors of a presentation, Michael [...]
Taming Our Monsters
Today the movie version of Maurice Sendak's 1963 children’s picture book, “Where the Wild Things Are” opens in theaters. When the book was first published, many people complained that it was too scary. Sendak’s response [...]